OverviewSuggest Edit

TransMedics is a medical device company. It develops organ transplant technologies. The Company provides a warm blood perfusion system that allows for a living organ transplant. 
TypePublic
Founded1998
HQAndover, MA, US
Websitetransmedics.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Dec 2019)109(+19%)
Job Openings22
Revenue (FY, 2020)$25.6 M(+9%)
Share Price (Oct 2021)$26.5(-4%)
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at TransMedics

Waleed Hassanein

Waleed Hassanein

Founder, President and CEO, Director
Stephen Gordon

Stephen Gordon

Chief Financial Officer
John Carey

John Carey

Vice President of Operations
Miriam Provost

Miriam Provost

Vice President of Global Regulatory Affairs
John Sullivan

John Sullivan

Vice President of Quality & Engineering
Ike Okonkwo

Ike Okonkwo

Vice President of Finance & Accounting
Show more

TransMedics Office Locations

TransMedics has an office in Andover
Andover, MA, US (HQ)
200 Minuteman Rd
Show all (1)

TransMedics Financials and Metrics

TransMedics Revenue

Embed Graph
View revenue for all periods
TransMedics's revenue was reported to be $25.64 m in FY, 2020
USD

Revenue (Q1, 2021)

7.1m

Gross profit (Q1, 2021)

4.8m

Gross profit margin (Q1, 2021), %

68.2%

Net income (Q1, 2021)

(7.9m)

EBIT (Q1, 2021)

(6.5m)

Market capitalization (15-Oct-2021)

733.4m

Closing stock price (15-Oct-2021)

26.5

Cash (31-Mar-2021)

26.7m

EV

741.4m
TransMedics's current market capitalization is $733.4 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

6.2m7.7m13.0m23.6m25.6m

Revenue growth, %

24%69%

Cost of goods sold

5.4m5.5m7.3m9.7m9.0m

Gross profit

766.0k2.1m5.7m13.9m16.6m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

1.5m2.2m1.9m2.5m2.9m4.0m4.7m5.7m7.2m7.5m3.4m7.1m7.1m

Cost of goods sold

1.2m1.4m1.4m1.6m1.7m1.9m2.1m2.3m3.0m2.7m1.5m2.1m2.2m

Gross profit

312.0k811.0k486.0k924.0k1.2m2.1m2.6m3.3m4.2m4.9m1.9m5.0m4.8m

Gross profit Margin, %

21%36%26%37%40%53%55%59%59%65%56%71%68%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

11.9m20.2m20.1m24.6m

Accounts Receivable

925.0k3.4m6.6m6.9m

Prepaid Expenses

477.0k1.8m1.5m2.3m

Inventories

8.0m9.3m11.2m11.9m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

12.2m47.2m20.4m24.7m51.2m21.4m26.7m

Accounts Receivable

5.1m7.1m6.5m6.1m4.4m6.1m7.4m

Prepaid Expenses

1.4m1.6m2.1m1.7m1.9m2.3m3.2m

Inventories

11.3m11.2m10.5m11.4m12.6m13.0m11.8m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(24.1m)(20.8m)(23.8m)(33.5m)(28.7m)

Depreciation and Amortization

426.0k630.0k769.0k1.2m

Inventories

(1.6m)(2.5m)(2.7m)(4.1m)

Accounts Payable

1.1m(735.0k)164.0k3.4m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(6.9m)(16.1m)(24.4m)(8.9m)(17.3m)(22.4m)(7.9m)

Depreciation and Amortization

245.0k534.0k866.0k371.0k745.0k1.1m445.0k

Inventories

(2.5m)(3.2m)(3.2m)(241.0k)(1.4m)(2.4m)(381.0k)

Accounts Payable

758.0k1.4m1.1m(2.4m)(3.8m)(6.4m)(82.0k)
Show all financial metrics

TransMedics Revenue Breakdown

Embed Graph

TransMedics revenue breakdown by business segment: 39.0% from OCS Lung net revenue, 45.8% from OCS Heart net revenue and 15.2% from OCS Liver net revenue

TransMedics revenue breakdown by geographic segment: 50.3% from United States and 49.7% from Outside the U.S.

TransMedics Online and Social Media Presence

Embed Graph

TransMedics News and Updates

TransMedics Announces Positive FDA Advisory Committee Vote for the OCS Liver System

ANDOVER, Mass., July 14, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that after review and discussion of...

TransMedics Group's stock is halted in advance of FDA committee meeting

Shares of TransMedics Group Inc. were halted on Wednesday in advance of an advisory committee meeting scheduled for the same day by the Food and Drug Administration. The committee is expected to review the company's premarket approval application for an investigational liver treatment device and th…

TransMedics Announces Scheduling of OCS Liver FDA Advisory Committee Meeting

ANDOVER, Mass., June 10, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the U.S. Food and Drug...

TransMedics to Present at the 39th Annual J.P. Morgan Healthcare Conference

ANDOVER, Mass., Dec. 24, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the management team...

TransMedics Reports Third Quarter 2020 Financial Results

ANDOVER, Mass., Nov. 4, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended...

TransMedics to Report Second Quarter 2020 Financial Results on August 5, 2020

ANDOVER, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for…
Show more

TransMedics Frequently Asked Questions

  • When was TransMedics founded?

    TransMedics was founded in 1998.

  • Who are TransMedics key executives?

    TransMedics's key executives are Waleed Hassanein, Stephen Gordon and John Carey.

  • How many employees does TransMedics have?

    TransMedics has 109 employees.

  • What is TransMedics revenue?

    Latest TransMedics annual revenue is $25.6 m.

  • What is TransMedics revenue per employee?

    Latest TransMedics revenue per employee is $235.2 k.

  • Who are TransMedics competitors?

    Competitors of TransMedics include Xhale, Bionode and Stroke Medical.

  • Where is TransMedics headquarters?

    TransMedics headquarters is located at 200 Minuteman Rd, Andover.

  • Where are TransMedics offices?

    TransMedics has an office in Andover.

  • How many offices does TransMedics have?

    TransMedics has 1 office.